GlaxoSmithKline Pharmaceuticals Limited has received a demand notice dated June 24, 2026, from the National Pharmaceutical Pricing Authority (NPPA) amounting to Rs 3.54 crore. GlaxoSmithKline Pharmaceuticals disclosed the development in a regulatory filing to BSE Limited and the National Stock Exchange of India under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The demand notice was issued under the Drug Price Control Order and relates to alleged pricing violations in scheduled pharmaceutical formulations.
The total demand of Rs 3.54 crore comprises Rs 1.23 crore on account of alleged overcharging and Rs 2.31 crore in accrued interest. GlaxoSmithKline Pharmaceuticals received the demand notice on June 24, 2026. The filing does not specify the exact time period for which the alleged overcharging pertains.
The NPPA has alleged that GlaxoSmithKline Pharmaceuticals overcharged in the sale of scheduled formulations by charging prices higher than the ceiling fixed or notified by the government or the pricing authority during the relevant period. The demand was calculated based on the difference between prices charged and the notified ceiling prices.
GlaxoSmithKline Pharmaceuticals stated that the demand notice will have no impact on the financial operations of the company. GlaxoSmithKline Pharmaceuticals has confirmed that it will file an appeal against the demand order from the NPPA.
The filing was submitted by Ajay Nadkarni, Vice President of Administration, Real Estate and Company Secretary of GlaxoSmithKline Pharmaceuticals. GlaxoSmithKline Pharmaceuticals shares are listed on both the BSE and the National Stock Exchange of India under the symbol GLAXO.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.